About: Employing bioactive compounds derived from Ipomoea obscura (L.) to evaluate potential inhibitor for SARS‐CoV‐2 main protease and ACE2 protein

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Employing bioactive compounds derived from Ipomoea obscura (L.) to evaluate potential inhibitor for SARS‐CoV‐2 main protease and ACE2 protein Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Employing bioactive compounds derived from Ipomoea obscura (L.) to evaluate potential inhibitor for SARS‐CoV‐2 main protease and ACE2 protein
Creator	Balasubramanian, Balamuralikrishnan Easwaran, Murugesh Kuchi Bhotla, Haripriya Meyyazhagan, Arun Pappusamy, Manikantan Anbuselvam, Jeeva Anbuselvam, Mohan Arumugam, Vijaya Gopalakrishnan, Velliyur Kanniyappan, Kaul, Tanushri Keshavarao, Sasikala Park, Sungkwon Poochi, Saravana
source	Medline; PMC
abstract	Angiotensin converting enzyme 2 (ACE2) and main protease (M(Pro)) are significant target proteins, mainly involved in the attachment of viral genome to host cells and aid in replication of severe acute respiratory syndrome‐coronaviruses or SARS‐CoV genome. In the present study, we identified 11 potent bioactive compounds from ethanolic leaf extract of Ipomoea obscura (L.) by using GC‐MS analysis. These potential bioactive compounds were considered for molecular docking studies against ACE2 and M(Pro) target proteins to determine the antiviral effects against SARS‐COV. Results exhibits that among 11 compounds from I. obscura (L.), urso‐deoxycholic acid, demeclocycline, tetracycline, chlorotetracycline, and ethyl iso‐allocholate had potential viral inhibitory activity. Hence, the present findings suggested that chemical constitution present in I. obscura (L.) will address inhibition of corona viral replication in host cells.
has issue date	2020-07-06(xsd:dateTime)
bibo:doi	10.1002/fft2.29
bibo:pmid	32838301
has license	cc-by
sha1sum (hex)	fb538752cbe7095f03a2228bfca919e0e9458f14
schema:url	https://doi.org/10.1002/fft2.29
resource representing a document's title	Employing bioactive compounds derived from Ipomoea obscura (L.) to evaluate potential inhibitor for SARS‐CoV‐2 main protease and ACE2 protein
has PubMed Central identifier	PMC7361879
has PubMed identifier	32838301
schema:publication	Food Front
resource representing a document's body	covid:fb538752cbe7095f03a2228bfca919e0e9458f14#body_text
is schema:about of	named entity 'SARS-CoV' named entity 'SARS-CoV-2' named entity 'derived' named entity 'genome' named entity 'target' named entity 'evaluate' named entity 'SARS-CoV' named entity 'coronaviruses' named entity 'ACE2' named entity 'Homo sapiens' named entity 'mass spectrometer' named entity 'RNA virus' named entity 'acute respiratory infection' named entity 'genome' named entity 'silica column' named entity 'Perkin Elmer' named entity 'RMSD' named entity '5.5' named entity 'virus' named entity 'hydrogen atom' named entity 'protein' named entity 'papain' named entity 'bioactive compounds' named entity 'human serum albumin' named entity 'PDB' named entity 'viral disease' named entity 'genome' named entity 'SARS' named entity 'mass spectra' named entity 'functional site' named entity 'ethanolic' named entity 'ADME' named entity 'receptor' named entity 'drug discovery' named entity 'medicinal properties' named entity 'COVID-19' named entity 'kidney' named entity 'amino acids' named entity 'hydrogen bond' named entity 'Italy' named entity 'feces' named entity 'viral replication' named entity 'rotary evaporator' named entity 'force field' named entity 'GC-MS' named entity 'Angiotensin converting enzyme 2' named entity 'deoxycholic acid' named entity 'spike protein' named entity 'hemorrhoids' named entity 'ACE2' named entity 'ionization states' named entity 'virus' named entity 'envelope protein' named entity 'bioactive compounds' named entity 'protease' named entity '1.2' named entity 'ACE2' named entity 'capsid' named entity 'protein' named entity 'dysentery' named entity 'Africa' named entity 'RNA' named entity 'drug discovery' named entity 'lungs' named entity 'human body' named entity 'protein structure' named entity 'demeclocycline' named entity 'hydrodistillation'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software